Last reviewed · How we verify
Cyclosporine ophthalmic gel vehicle
Cyclosporine ophthalmic gel vehicle is a Calcineurin inhibitor Small molecule drug developed by Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.. It is currently in Phase 3 development for Dry eye disease (keratoconjunctivitis sicca), Ocular surface inflammation. Also known as: Vehicle.
Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation and reduces inflammatory cytokine production in the eye.
Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation and reduces inflammatory cytokine production in the eye. Used for Dry eye disease (keratoconjunctivitis sicca), Ocular surface inflammation.
At a glance
| Generic name | Cyclosporine ophthalmic gel vehicle |
|---|---|
| Also known as | Vehicle |
| Sponsor | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. |
| Drug class | Calcineurin inhibitor |
| Target | Calcineurin |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Cyclosporine binds to cyclophilin and inhibits calcineurin, a phosphatase required for T-cell activation and IL-2 production. In ophthalmic formulation, it reduces ocular surface inflammation by decreasing T-lymphocyte infiltration and pro-inflammatory cytokine release, thereby improving tear production and reducing dry eye symptoms.
Approved indications
- Dry eye disease (keratoconjunctivitis sicca)
- Ocular surface inflammation
Common side effects
- Ocular irritation or burning
- Conjunctival hyperemia
- Foreign body sensation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyclosporine ophthalmic gel vehicle CI brief — competitive landscape report
- Cyclosporine ophthalmic gel vehicle updates RSS · CI watch RSS
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. portfolio CI
Frequently asked questions about Cyclosporine ophthalmic gel vehicle
What is Cyclosporine ophthalmic gel vehicle?
How does Cyclosporine ophthalmic gel vehicle work?
What is Cyclosporine ophthalmic gel vehicle used for?
Who makes Cyclosporine ophthalmic gel vehicle?
Is Cyclosporine ophthalmic gel vehicle also known as anything else?
What drug class is Cyclosporine ophthalmic gel vehicle in?
What development phase is Cyclosporine ophthalmic gel vehicle in?
What are the side effects of Cyclosporine ophthalmic gel vehicle?
What does Cyclosporine ophthalmic gel vehicle target?
Related
- Drug class: All Calcineurin inhibitor drugs
- Target: All drugs targeting Calcineurin
- Manufacturer: Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Dry eye disease (keratoconjunctivitis sicca)
- Indication: Drugs for Ocular surface inflammation
- Also known as: Vehicle
- Compare: Cyclosporine ophthalmic gel vehicle vs similar drugs
- Pricing: Cyclosporine ophthalmic gel vehicle cost, discount & access